Huma partners with Eckuity Capital and acquires Aluna

Global healthcare AI firm Huma Therapeutics has announced a partnership with Eckuity Capital and the acquisition of Aluna, a US company specialising in intelligent remote monitoring and management of respiratory diseases.

Acquiring Aluna will allow Huma to expand its reach in respiratory health, adding more than 150 US-based health systems and clinic networks to its global footprint.

As part of the integration, Aluna’s solutions will be relaunched on the Huma Cloud Platform to enhance its capabilities.

Dan Vahdat, founder and chief executive of Huma, said: “Today’s announcements mark a new chapter for Huma as we strive to build the most impactful healthcare company in the world.

“By integrating Aluna’s leading respiratory monitoring solutions into our platform and working to secure growth capital for further acquisitions, we are creating a complete ecosystem to deliver even greater value to health systems, life sciences, and most importantly, patients around the world.”

Existing Aluna customers will gain access to Huma’s portfolio of disease management programs, spanning asthma, chronic obstructive pulmonary disease, sleep apnea, and related conditions, serving approximately 500,000 contracted lives across these areas.

Charvi Shetty, chief executive at Aluna, said: “Joining forces with Huma offers a remarkable opportunity to amplify our impact and extend the reach of our AI-driven respiratory management platform to a wider patient base worldwide.

“We are excited about the prospect of integrating our technology into the Huma Cloud Platform, creating a truly holistic digital health solution that empowers both patients and healthcare professionals in the effective management of respiratory conditions.”

The strategic collaboration with Eckuity Capital will help provide the resources necessary to advance Huma’s mergers and acquisitions strategy, with the goal of acquiring complementary companies to build a digital ecosystem supporting health systems, pharmaceutical companies and patients worldwide.

Youssef Sebban, managing partner at Eckuity Capital, said: “We help Huma acquire companies that, on their own, may not fully realise their potential but when integrated into Huma’s cloud platform, become highly complementary and transformative.

“This synergy not only amplifies their impact on the healthcare ecosystem but also drives outsized value creation for investors and shareholders.”

Huma’s disease-agnostic Software-as-a-Medical-Device platform received US Food and Drug Administration class II clearance in June 2023, enabling companies to launch their own algorithm innovations more quickly to the platform and allowing AI algorithms for disease prognostication and recommendations for treatment.

The firm’s latest acquisition follow the purchase of GP online consultation and digital triage start-up eConsult for an undisclosed amount in October 2024 and an $80 million (£60m) Series D funding round in July 2024, which took the total amount raised by Huma to more than $300m (£226m).

Huma’s platform supports more than 4,500 hospitals and clinics and engages more than 50m individuals across over 70 countries.